RA CAPITAL MANAGEMENT, L.P. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001346824
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 84 positions · Total reported value $11.51B · Top-10 concentration 60.4% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 42.6% · 16 new · 10 cut · 17 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +14.6% · vs SPY -0.2% · Prev Value $9.44B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2026 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 84 equity positions with a combined reported value of $11.51B. The filing implies a focused portfolio: its ten largest positions account for 60.4% of reported value. HoldingsHub classifies the profile as Large / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2026 were ASND ($2.74B), PBLS ($791.91M), RYTM ($740.22M). By sector, the heaviest allocations are Health Care 98.1%, Financials 0.2%. Versus the prior quarter, allocation shifted toward Health Care (+1.4pp) and away from Other (-1.3pp).
Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 16 new positions, trimmed 10 and fully exited 17, a turnover rate of 42.6% of positions. The portfolio's overlap with the prior quarter was 67% of names.
The largest new positions opened in Q2 2026 were PBLS ($791.91M), COAG ($286.81M), ABVX ($150.92M).
Of the 17 positions fully exited versus the prior quarter, the largest were DNTH ($219.18M), PRAX ($120.43M), SRPT ($84.92M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
- PBLS PARABILIS MEDICINES INC COM · $791.91M
- COAG HEMAB THERAPEUTICS HOLDINGS · $286.81M
- ABVX ABIVAX SA · $150.92M
- ORKA ORUKA THERAPEUTICS INC · $147.95M
- NTLA INTELLIA THERAPEUTICS INC · $76.60M
- DFTX DEFINIUM THERAPEUTICS INC COM SHS · $70.56M
- SANA SANA BIOTECHNOLOGY INC · $65.44M
- PRLD PRELUDE THERAPEUTICS INC · $34.52M
Fully Exited (vs previous quarter)
- DNTH DIANTHUS THERAPEUTICS INC · prev qtr: $219.18M
- PRAX PRAXIS PRECISION MEDICINES I · prev qtr: $120.43M
- SRPT SAREPTA THERAPEUTICS INC · prev qtr: $84.92M
- SYRE SPYRE THERAPEUTICS INC · prev qtr: $81.79M
- FULC FULCRUM THERAPEUTICS INC · prev qtr: $46.43M
- OLMA OLEMA PHARMACEUTICALS INC · prev qtr: $38.77M
- DSGN DESIGN THERAPEUTICS INC · prev qtr: $31.63M
- TVTX TRAVERE THERAPEUTICS INC · prev qtr: $22.19M
Insider Transactions (Form 4)
Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-02 | Buy | Bambusa Therapeutics, Inc. | 164,891 | $16.00 | SEC filing |
| 2026-11-02 | Buy | Bambusa Therapeutics, Inc. | 2,335,109 | $16.00 | SEC filing |
| 2026-11-02 | Conversion | Bambusa Therapeutics, Inc. | 1,331,080 | — | SEC filing |
| 2026-11-02 | Conversion | Bambusa Therapeutics, Inc. | 3,144,858 | — | SEC filing |
| 2026-10-30 | Buy | Bambusa Therapeutics, Inc. | 263,911 | $14.92 | SEC filing |
| 2026-10-30 | Buy | Bambusa Therapeutics, Inc. | 189,909 | $14.23 | SEC filing |
| 2026-10-29 | Sell | LENZ Therapeutics, Inc. | 107,170 | $3.36 | SEC filing |
| 2026-10-29 | Sell | LENZ Therapeutics, Inc. | 451,998 | $3.36 | SEC filing |
Fund Profile
RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.
Investment Approach
Focuses on healthcare sector investments
Long-term, value-oriented strategy
Deep fundamental research and analysis
Asset Classes & Strategy
Primarily invests in public equities
Also manages private investments in healthcare companies
Concentrated portfolio approach with significant positions in healthcare companies
Key Personnel
Peter Kiernan: Founder and portfolio manager
Team of experienced investment professionals with healthcare expertise
Notable Facts
Founded in 2002
Manages approximately $16.4 billion in assets
Files SEC Form 13F for US equity positions
This profile is based on publicly available information and should not be considered as official disclosure from the firm.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
10.28M | $2.74B | 23.83% | Hold | |
| 2 |
|
28.93M | $791.91M | 6.88% | New | |
| 3 |
|
6.67M | $740.22M | 6.43% | Hold | |
| 4 |
|
11.47M | $667.02M | 5.80% | Hold | |
| 5 |
|
9.91M | $435.72M | 3.79% Form 4 · 2 → |
Hold | |
| 6 |
|
12.20M | $389.62M | 3.39% | Hold | |
| 7 |
|
8.39M | $341.00M | 2.96% | Reduce | |
| 8 |
|
9.55M | $323.66M | 2.81% | Hold | |
| 9 |
|
7.81M | $286.81M | 2.49% | New | |
| 10 |
|
7.00M | $234.29M | 2.04% | Hold | |
| 11 |
|
7.26M | $215.43M | 1.87% | Hold | |
| 12 |
|
7.69M | $207.55M | 1.80% | Hold | |
| 13 |
|
7.64M | $205.28M | 1.78% | Reduce | |
| 14 |
|
2.45M | $179.21M | 1.56% | Hold | |
| 15 |
|
8.02M | $178.55M | 1.55% | Hold | |
| 16 |
|
17.96M | $174.17M | 1.51% | Add | |
| 17 |
|
11.19M | $171.87M | 1.49% | Hold | |
| 18 |
|
23.56M | $160.41M | 1.39% | Hold | |
| 19 |
|
15.83M | $158.27M | 1.38% | Hold | |
| 20 |
|
26.98M | $156.73M | 1.36% Form 4 · 1 → |
Hold | |
| 21 |
|
1.25M | $153.94M | 1.34% | Reduce | |
| 22 |
|
1.13M | $150.92M | 1.31% | New | |
| 23 |
|
1.55M | $147.95M | 1.29% | New | |
| 24 |
|
11.30M | $147.36M | 1.28% Form 4 · 4 → |
Hold | |
| 25 |
|
12.04M | $120.24M | 1.04% | Add | |
| 26 |
|
5.74M | $109.13M | 0.95% | Add | |
| 27 |
|
10.86M | $87.00M | 0.76% | Hold | |
| 28 |
|
5.27M | $84.92M | 0.74% | Add | |
| 29 |
|
3.67M | $81.57M | 0.71% | Hold | |
| 30 |
|
4.53M | $76.60M | 0.67% | New | |
| 31 |
|
2.21M | $71.68M | 0.62% | Hold | |
| 32 |
|
1.50M | $70.56M | 0.61% | New | |
| 33 |
|
12.72M | $67.30M | 0.58% | Add | |
| 34 |
|
5.05M | $67.16M | 0.58% | Hold | |
| 35 |
|
18.75M | $65.44M | 0.57% | New | |
| 36 |
|
2.40M | $62.42M | 0.54% | Hold | |
| 37 |
|
667.21K | $61.78M | 0.54% | Hold | |
| 38 |
|
20.99M | $56.05M | 0.49% | Hold | |
| 39 |
|
42.81M | $54.80M | 0.48% | Reduce | |
| 40 |
|
9.45M | $49.11M | 0.43% | Add | |
| 41 |
|
3.49M | $46.44M | 0.40% | Hold | |
| 42 |
|
2.40M | $44.22M | 0.38% Form 4 · 1 → |
Reduce | |
| 43 |
|
17.75M | $43.50M | 0.38% | Hold | |
| 44 |
|
1.31M | $42.36M | 0.37% | Reduce | |
| 45 |
|
1.67M | $40.97M | 0.36% | Add | |
| 46 |
|
8.00M | $37.36M | 0.33% | Hold | |
| 47 |
|
318.55K | $37.29M | 0.32% | Hold | |
| 48 |
|
1.51M | $36.31M | 0.32% | Hold | |
| 49 |
|
20.06M | $36.12M | 0.31% | Hold | |
| 50 |
|
6.48M | $34.52M | 0.30% | New | |
FAQ
What did RA CAPITAL MANAGEMENT, L.P. buy in 2026-Q2?
In its 2026-Q2 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 84 equity positions worth $11.51B in aggregate; its largest disclosed positions were ASND ($2.74B), PBLS ($791.91M), RYTM ($740.22M).
How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?
RA CAPITAL MANAGEMENT, L.P. reported $11.51B of long equity holdings across 84 positions as of 2026-Q2. Top-10 holdings account for 60.4% of reported value.
What is RA CAPITAL MANAGEMENT, L.P.'s investment style?
HoldingsHub classifies the portfolio as Large / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.